Sanofi gets paid to borrow three year money

The extraordinary conditions in Europe’s investment grade corporate bond market, in which three issuers in succession had printed multi-tranche bonds this week with no new issue premiums, produced a new bizarre result on Wednesday when Sanofi, one of the market’s tightest-trading issuers, took its turn.
The French pharmaceutical company, rated A1/AA with stable outlooks, with an extra AA from Scope Ratings, is well known for being price-conscious and often pricing bonds at low coupons and tight spreads.
The Brexit saga had just reeled to yet another absurd climax on Tuesday night, when the House ...Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: subs@globalcapital.com
Or sign up for a trial to gain full access to the entire site for a limited period.
Corporate access
To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.